NOTICE TO THE MARKET

Grupo Biotoscana announces new initiatives for LENVIMA

Montevideo, Uruguay, March 12, 2018. GBT-Grupo Biotoscana (B3: GBIO33), a leading biopharmaceutical company in Latin America, announces to its shareholders and the market in general that, last week, our partner, Eisai Co., Ltd., announced a separate arrangement for our key partnered drug LENVIMA^® (lenvatinib).

Under a new agreement between Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth N.J., U.S.A (known as MSD outside the United States and Canada), Eisai and MSD co-develop and co-commercialize LENVIMA^® (lenvatinib mesylate), as monotherapy and in combination with MSD’s anti-PD-1 therapy, KEYTRUDA^® (pembrolizumab).

GBT reinforces its commitment to commercialize LENVIMA^® (lenvatinib) and clarifies that the arrangement between Eisai and MSD does not change, GBT’s rights to LENVIMA^® (lenvatinib), which were the subject of a previous agreement between GBT and Eisai, and GBT will continue to book 100% of the sales of LENVIMA^® (lenvatinib) in GBT‘s territory.

GBT – Grupo Biotoscana.
ir@grupobiotoscana.com

To access the PDF version, please click here.

Updated on 01/02/2019 at 04:38 pm